Dear Members of the HMS Community,
I would like to congratulate Kenneth Anderson and Paul Richardson of Dana–Farber Cancer Institute and Harvard Medical School, Alfred Goldberg of Harvard Medical School and Julian Adams of Infinity Pharmaceuticals for their selection as this year’s Warren Alpert Foundation Prize honorees.
This group of outstanding scientists and physicians received the prize for their extraordinary accomplishments in taking bortezomib (commercially known as Velcade) from the lab bench, as part of a fundamental inquiry into cellular protein homeostasis, to its current status as a frontline therapy for treating patients with multiple myeloma. Their joint selection celebrates both the fundamental science that provided the foundation and spark for subsequent studies, and the manner in which the discoveries were built upon by clinical science and collaboration within the academy and with industry to benefit human health. Each honoree will discuss his unique contributions to the ultimate development of bortezomib at this year’s symposium, which will take place on Monday, Sept. 24, 2:30-5:30 p.m., at the New Research Building located at 77 Avenue Louis Pasteur. Program details are available at http://hms.harvard.edu/content/alpert-prize-honors-developers-pioneering-cancer-drug.
The Warren Alpert Foundation Prize honors individuals whose discoveries have translated into, or show great promise of being translated into, treatments of human disease. First awarded in 1987, and associated with HMS since that time, the prestigious Prize garners nominations from many of the world’s foremost physicians and scientists. Further information on the Warren Alpert Foundation Prize can be found at http://www.warrenalpert.org/foundation/.